Riboxin - instructions for use, dose, side effects, contraindications

Excipients: potato starch 0.024268 g, methyl cellulose, water soluble 0.002280 g, sucrose (sugar) 0.035896 g, calcium stearate 0.002700 g, povidone (low molecular weight medical polyvinylpyrrolidone 12600 ± 2700) 0.004856 g;

shell: methylcellulose water soluble 0.002325 g, polysorbate (tween-80) 0.00343 g, titanium dioxide 0.00082 g, beeswax 0,00036 g, dye "quinoline yellow" (E-104) 0.000065 g.

Description:

The tablets covered with a film membrane, from light yellow to greenish-yellow color, round, biconcave. On the cross-section, two layers are visible, the inner layer is white.

Pharmacotherapeutic group:metabolic

ATX: & nbsp

C.01.E.B Other drugs for the treatment of heart disease

Pharmacodynamics:

Metabolic agent, a precursor of adenosine triphosphate; has antihypoxic, metabolic and antiarrhythmic effects. Increases the energy balance of the myocardium, improves coronary circulation, prevents the consequences of intraoperative kidney ischemia. It takes a direct part in the exchange of glucose and promotes the activation of metabolism in conditions of hypoxia and in the absence of adenosine triphosphate. Activates the metabolism of pyruvic acid to ensure a normal process of tissue respiration, and also promotes the activation of xanthine dehydrogenase.Stimulates the synthesis of nucleotides, enhances the activity of certain enzymes of the Krebs cycle. Penetrating into cells, increases the energy level, has a positive effect on the metabolic processes in the myocardium, increases the strength of the heart contractions and promotes more complete relaxation of the myocardium in diastole, resulting in an increase in the shock volume of blood. Reduces the aggregation of platelets.

Pharmacokinetics:

Xopowo absorbed in the gastrointestinal tract. Metabolised in the liver with the formation of glucuronic acid and its subsequent oxidation. In a small amount is excreted by the kidneys.

Indications:

Assign adults in the complex therapy of coronary heart disease, after a heart attack, myocardial infarction, heart rhythm disorders due to the use of cardiac glycosides.

Assign with hepatitis, cirrhosis, fatty liver, caused by alcohol or drugs, with urocoppororphy.

Contraindications:

Hypersensitivity to the drug, gout, hyperuricemia.

Fructose intolerance and glucose / galactose absorption disorder or sugar / isomaltase deficiency.

Carefully:

Renal insufficiency, diabetes mellitus.

Pregnancy and lactation:

The use of the drug during pregnancy is contraindicated.

For the duration of treatment, stop breastfeeding.

Dosing and Administration:

Assign inside before eating.

The maximum daily dose of the drug for oral administration is 0.6-2.4 g. In the first days of treatment, the daily dose is 0.6-0.8 g (200 mg 3-4 times a day).

In case of good tolerance, the dose is increased (2-3 days) to 1.2 g (0.4 g 3 times a day), if necessary - up to 2.4 g per day.

The duration of the course is from 4 weeks to 1.5-3 months.

With urocoppororphy, the maximum daily dose is 0.8 g (200 mg 4 times a day). The course of treatment is 1-3 months.

Side effects:

Allergic reactions are possible in the form of hives, itchy skin, skin hyperemia (drug withdrawal is required).

Rarely with the treatment of the drug raises the concentration of uric acid in the blood and exacerbation of gout (with prolonged use).

Overdose:

Cases of overdose are unknown.

Interaction:

Immunosuppressants (immunoglobulin antithymocyte, ciclosporin, gamma-D-glutamyl-D-tryptophan, etc.) with simultaneous use reduce the effectiveness of Riboxin.

Special instructions:

During the treatment with Riboxin, the concentration of uric acid in the blood and urine should be monitored.

Information for patients with diabetes mellitus: 1 tablet of the drug corresponds to 0.003 bread units.

Effect on the ability to drive transp. cf. and fur:

Does not affect the ability to drive vehicles and manage mechanisms that require increased concentration.

Form release / dosage:

Tablets, film-coated, 200 mg.

Packaging:

For 10 tablets in a contour mesh box made of polyvinylchloride film and aluminum foil printed lacquered.

50 tablets in cans of glass glass of orange glass, sealed with polyethylene caps, or in polymer cans.

5 contour packs or a jar along with instructions for use are placed in a pack of cardboard.

Storage conditions:

In a dry, dark place at a temperature of 15 to 25 ° C.

Keep out of the reach of children.

Shelf life:

3 years.

Do not use after the time specified on the package.

Terms of leave from pharmacies:On prescription

Registration number:P N000802 / 02-2002

Date of registration:03.10.2008

The owner of the registration certificate:DALHIMFARM, OJSC DALHIMFARM, OJSC Russia

Manufacturer: & nbsp

DALHIMFARM, OJSC Russia

Representation: & nbspDALHIMFARM, OJSCDALHIMFARM, OJSC

Information update date: & nbsp23.10.2015

Illustrated instructions

Instructions

Riboxin (Riboxin)